ClinicalTrials.gg
Status unknownNCT05232149Updated Jan 12, 2023

A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

A Phase 2 interventional study of Orelabrutinib( lower dose) and Orelabrutinib( higher dose) in Primary Immune Thrombocytopenia, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Status unknown at 9 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-12.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
118th of 167
30 · median 62
Started
2022
with 16 others
Phase 2
65 of 185
33 open now
Registered
81st of 185
by date

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 118th largest by planned enrollment of the 167 interventional ones that give a count, is one of 17 that started in 2022, is one of 65 in phase 2, and was the 81st registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

The study is designed to be a randomized, open, multi-center, phase IIa/IIb seamless adaptive trial.

Phase IIa: The study consists of a screening period, a core treatment period, an open label extension period, and a safety follow-up period Phase IIb: At present, a preliminary exploratory study (i.e., phase IIa study) will be conducted first. The design of the phase IIb study (including the selection of populations) will be clarified after a relatively clear understanding of the therapeutic effect, value, risks and benefits of the BTK inhibitor for ITP is obtained.

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • Persistent or chronic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects have had a detailed understanding of the nature, significance, possible benefits, possible inconveniences, and potential risks of the trial, understood the study procedures, and voluntarily signed a written ICF before the study.
  2. Males or females aged from 18 to 80 years (including the marginal values).
  3. With a body weight of ≥ 35 kg at screening.
  4. Diagnostic criteria:the diagnosis of persistent (3-12 months) or chronic (≥ 12 months) ITP is met
  5. Patients who have failed at least 1 prior standard therapy for ITP, or who have failed to tolerate a standard therapy.
  6. Women of must take a complementary barrier method of in combination with a highly effective method of contraception at screening, throughout the trial, and within 90 days after the last dose of the drug.
  7. The mean of two counts is less than 30 × 109/L and no platelet count is greater than 35 × 109/L during the screening visit and/or before the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Severe hemorrhage occurred within 4 weeks prior to screening.
  2. Subjects suffer from severe ITP at screening
  3. Subjects have other diseases which mention in protocol
  4. Subjects develop intracranial hemorrhage within 6 months prior to screening.
  5. Active and uncontrollable infection
  6. Subjects have a history of coagulopathy other than ITP
  7. Subjects with a history of .
  8. History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation.
  9. Subjects with a known history of to the drug as described in the Protocol, or any ingredients.
  10. Subjects with a Medication history and surgical history which mention in protocol
  11. Subjects do not meet the criterion of the laboratory test in protocol

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Lower Dose

    Orelabrutinib is a white, round, uncoated tablet

    Drug: Orelabrutinib( lower dose)

  • Experimental
    Higher Dose

    Orelabrutinib is a white, round, uncoated tablet

    Drug: Orelabrutinib( higher dose)

Interventions

  • Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia

  • Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with the platelet count of ≥ 50 × 109/L after 12 weeks of treatment

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of subjects who achieve a complete response (CR) over treatment time. CR is defined as a post-treatment platelet count of ≥100 × 109/L

    Time frame: 25 weeks

  2. Occurrence of treatment emergent adverse events (TEAE) and treatment-related adverse events (TRAE) were evaluated according to severity

    Time frame: 25 weeks

Other outcomes

  1. Cmax

    To obtain pharmacokinetic (PK) data of Orelabrutinib include the peak plasma concentration (Cmax)

    Time frame: 25 weeks

07

Study locations

9 of 9 sites recruiting
  • Hainan People's Hospital
    HaiKou, Hainan 570100, China
    Recruiting
    • Li'e Lin · Contact
  • Henan Tumor Hospital
    ZhengZhou, Henan 450000, China
    Recruiting
    • Hu Zhou · Contact
  • The First Affiliated Hospital of Zhengzhou University
    ZhengZhou, Henan 450000, China
    Recruiting
    • Fang Wang · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    WuHan, Hubei 430000, China
    Recruiting
    • Heng Mei, PhD · Contact
  • Yichang Central People's Hospital
    YiChang, Hubei 443000, China
    Recruiting
    • Jingming Guo · Contact
  • Wuxi People's Hospital
    WuXi, Jiangsu 214000, China
    Recruiting
    • Xin Zhou · Contact
  • Affiliated Hospital of Xuzhou Medical University
    XuZhou, Jiangsu 221000, China
    Recruiting
    • Zhenyu Li · Contact
  • First Hospital of Nanchang University
    NanChang, Jiangxi 330000, China
    Recruiting
    • Ruibin Huang · Contact
  • QiLu Hospital of Shandong University
    JiNan, Shandong 250012, China
    Recruiting
    • Ming Hou · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2023, 22 months after the start.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Feb 9, 2022
StartActual
Feb 21, 2022
Primary completionEst.
Dec 30, 2023
CompletionEst.
Dec 30, 2024
Last update
Jan 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05232149
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Feb 21, 2022
Primary completion
Dec 30, 2023 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Jan 12, 2023

Study contacts

Ming Hou, PhD
Contact
houming@medmail.com.cn
18560087007

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion